Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of cisplatin micelle injection (HA132) in advanced malignant solid tumors
CTR20221897Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in Nonhematologic neoplasms, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-limiting toxicities, Maximum tolerated dose and 3 more. Started Sep 2022; status: active.
02
Drugs
cisplatin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221897.